Contact this trialFirst, we need to learn more about you.
Kinase Inhibitor
Ruxolitinib + Abemaciclib for Myelofibrosis
Recruiting1 awardPhase 1
New York, New York
This trial is testing if using two drugs, ruxolitinib and abemaciclib, together can help treat a specific type of blood cancer. The target group is people with primary or post-polycythemia vera/essential thrombocythemia myelofibrosis. The drugs work by blocking proteins that cancer cells need to grow and divide. Ruxolitinib is a targeted drug approved for the treatment of myelofibrosis.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service.
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service